Inpharmatica Announces ISO 9001 Certification for its ADME Business
News May 15, 2006
Inpharmatica Ltd. has announced the award of ISO 9001:2000 quality certification for its comprehensive ADME business, Admensa™.
The internationally accepted ISO 9001 Certification recognises Inpharmatica's commitment to a quality of service and customer care within its Admensa division.
The high level of customer care and service is bringing Inpharmatica an expanding list of international companies who have chosen to work with Inpharmatica to address their ADME needs.
40 customers have signed up to use Admensa, including recent additions Ark Therapeutics Group PLC, KuDOS Pharmaceuticals Limited, iQur Limited and Canbex Therapeutics Limited, a spin out from UCL's Wolfson Institute.
Admensa is designed to offer a combination of ADME optimisation expertise, proprietary in silico tools, laboratory services and consulting, to enable early selection of compounds with an optimal balance of drug like properties.
A module of Admensa, Admensa Interactive™, Inpharmatica's in silico optimisation platform for drug discovery scientists, has recently been enhanced to offer improved QSAR ADME models, P450 metabolism models and unique compound prioritisation and selection methods within an intuitive, interactive design environment.
Admensa itself is an integral component of Inpharmatica's gene-to-candidate technology platform which integrates biology- and chemistry-based drug discovery activities.
The complete platform is designed to optimise target selection based on druggability, and enables identification of hits and selection of high quality leads and pre-clinical candidates, which are prioritised on the basis of good drug-like characteristics and clinical indication.
Commenting on the announcement, John Lisle, Inpharmatica's CEO, said, "This ISO 9001 certification means that Inpharmatica's customers can be even more confident that they will receive an excellent product and an excellent level of service and customer care."
"We have already seen high levels of customer satisfaction and the company is enjoying the extra sales that this brings."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019